Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. (Nasdaq: PCVX) is a pioneering biopharmaceutical company based in San Carlos, California, dedicated to developing high-fidelity vaccines to protect against serious bacterial infections. Vaxcyte aims to improve global health through innovative vaccines designed to prevent diseases that conventional options fail to address effectively.
The company's flagship product, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) designed to provide broad-spectrum protection against invasive pneumococcal disease (IPD). VAX-24 is engineered to cover more strains than the current leading vaccines, addressing a significant unmet need in both adult and pediatric populations. Vaxcyte's advanced cell-free protein synthesis platform, XpressCF™, is pivotal in developing these complex conjugate vaccines, allowing for efficient production and enhanced immunogenicity.
Vaxcyte's pipeline includes VAX-31, a next-generation 31-valent PCV, currently in Phase 1/2 clinical trials. VAX-31 aims to achieve the broadest coverage of any PCV to date, targeting 95% of IPD strains circulating in the U.S. adult population. Additionally, the company is developing other promising vaccine candidates such as VAX-A1 for Group A Strep infections, VAX-PG for periodontal disease, and VAX-GI for Shigella prevention.
Recent milestones include the successful completion of enrollment in the VAX-31 Phase 1/2 trial and the VAX-24 infant Phase 2 study. The FDA granted Breakthrough Therapy designation to VAX-24, reflecting its potential to offer substantial improvements over existing treatments. Vaxcyte is on track to advance VAX-24 into Phase 3 trials, with topline data anticipated by 2025.
Financially, Vaxcyte is robust, supported by $1.4 billion in recent follow-on equity financings to advance its vaccine candidates and expand its manufacturing capabilities.
For more information, visit www.vaxcyte.com.
Vaxcyte, Inc. (Nasdaq: PCVX) reported Q1 2021 financial results and updates on its vaccine pipeline. As of March 31, 2021, it had $370.9 million in cash. R&D expenses decreased to $17.3 million, while G&A expenses rose to $5.9 million, resulting in a net loss of $21.2 million. The company is progressing with its 24-valent pneumococcal vaccine, VAX-24, aiming to submit an IND application to the FDA by mid-2022. Vaxcyte also appointed Janet Graesser as Vice President of Corporate Communications, enhancing its strategic communications.
Vaxcyte announced the publication of preclinical data for its investigational VAX-24 vaccine in Vaccine, showing that all 24-valent serotypes in VAX-24 elicited robust immune responses compared to existing vaccines. This 24-valent pneumococcal conjugate vaccine targets strains not covered by the current 13-valent vaccine, addressing a significant unmet medical need in preventing invasive pneumococcal disease. Vaxcyte plans to submit an Investigational New Drug application to the FDA for VAX-24, advancing towards clinical trials.
Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the BofA Securities 2021 Health Care Conference set for May 13, 2021, at 3:30 PM ET. The event will feature company management presenting the latest developments in their innovative vaccines aimed at combating infectious diseases. A live webcast will be accessible via their official website, with a replay available for 30 days post-conference. Vaxcyte is noted for its advanced vaccine candidates including VAX-24, addressing pneumococcal disease, and VAX-XP for broader strain coverage.
Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 1:30 p.m. ET. The event aims to showcase Vaxcyte's innovative vaccine development efforts, including its lead candidate, VAX-24, a preclinical pneumococcal conjugate vaccine designed for preventing invasive pneumococcal disease. A live webcast will be available through the company's website, with a replay offered for 30 days post-conference. Vaxcyte is focused on creating novel vaccines to address common infectious diseases globally.
Vaxcyte, Inc. (Nasdaq: PCVX) reported its financial results for Q4 and full year 2020, highlighting a net loss of $20.7 million for Q4 and $89.2 million for the year. The company announced a revised timeline for its VAX-24 IND application submission, now expected between January and June 2022, due to manufacturing constraints. Key advancements included new immunogenicity data for its VAX-XP program and the final candidate nomination for VAX-A1. Vaxcyte's cash position increased to $386.2 million, supported by its IPO and Series D financing in 2020.
Vaxcyte, Inc. (Nasdaq: PCVX) will report its financial results for Q4 and the full year 2020 after market close on March 29, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss the results and provide a business update. Vaxcyte develops innovative vaccines aimed at preventing major infectious diseases, leveraging its cell-free protein synthesis platform, XpressCF. The lead candidate, VAX-24, is a preclinical 24-valent pneumococcal conjugate vaccine. Additional candidates include VAX-XP, VAX-A1, and VAX-PG.
Vaxcyte published preclinical data for its novel Group A Streptococcus vaccine candidate, VAX-A1, in the journal Infectious Microbes & Diseases. This vaccine aims to combat Group A Strep, a leading cause of bacterial infections, including strep throat, which significantly contributes to global antibiotic prescriptions. The study exhibited that the vaccine could effectively protect against Group A Strep infections in mouse models without cross-reactivity to human tissues. Vaxcyte is advancing toward a global health solution amid rising antibiotic resistance concerns.
Vaxcyte, Inc. has announced the promotion of Andrew Guggenhime to President and Chief Financial Officer, effective January 1, 2021. This transition reflects the company's leadership evolution as it aims to scale operations and advance its vaccine pipeline, especially the pneumococcal vaccine candidate VAX-24. Guggenhime, who joined Vaxcyte in May 2020, brings over two decades of financial and operational experience in the healthcare sector.
Vaxcyte focuses on developing innovative vaccines to combat infectious diseases globally, leveraging its cell-free protein synthesis platform for vaccine creation.
Vaxcyte, formerly SutroVax, announced participation in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on December 2, 2020, at 1:50 PM ET. The event aims to discuss the company’s innovative vaccine developments targeting widespread infectious diseases. A live webcast will be available on the company’s website, with a replay offered for 30 days post-event. Vaxcyte is advancing several candidates, including VAX-24, a preclinical 24-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease.
Vaxcyte announced its Q3 2020 financial results, highlighting a net loss of $21 million compared to $11.3 million in Q3 2019. The company’s cash position improved significantly to $397 million, up from $59 million at the end of 2019, following its IPO and Series D financing. Vaxcyte reported R&D expenses of $16.4 million, primarily due to increased manufacturing costs for its VAX-24 program, and G&A expenses rose to $4.9 million. Key milestones include an anticipated IND filing for VAX-24 in the second half of 2021 and ongoing progression in its vaccine pipeline.
FAQ
What is the current stock price of Vaxcyte (PCVX)?
What is the market cap of Vaxcyte (PCVX)?
What is Vaxcyte, Inc.'s primary focus?
What are the key products in Vaxcyte's pipeline?
What makes VAX-24 different from existing vaccines?
What is the XpressCF™ platform?
What recent milestones has Vaxcyte achieved?
When is Vaxcyte expected to release data from its VAX-24 Phase 3 trials?
What financial support does Vaxcyte have for its projects?
Where can I find more information about Vaxcyte?
What is VAX-31 and its significance?
What other vaccine candidates is Vaxcyte developing?
